EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The Unit has been issued GMP Certification from ANVISA-Brazil
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Subscribe To Our Newsletter & Stay Updated